Friday, July 10, 2026

pharma · Hepatitis B, Chronic · Cancer

EmeraMed

Immunocore Ireland is a pharma organization headquartered in GB. Primary therapeutic focus areas include Hepatitis B, Chronic, Cancer, Chronic HIV infection, Advanced PRAME Positive Cancers, Previously untreated advanced

Ranelagh, IE HQ
2007 Founded
7 Employees
EMA registrant Type
Company details
Status
Public
HQ
Ranelagh, IE
Founded
2007
Employees
7
Programs
5
Drugs
9
Patents
0
Clinical program

Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers

Phase 1 · other · Advanced PRAME Positive Cancers

Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers for Advanced PRAME Positive Cancers is a Phase 1 program (other) at Immunocore Ireland Limited with 1 ClinicalTrials.gov record(s).

Internal code IMC-P115C-1005

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Immunocore Ireland Limited
Phase
Phase 1
Modality
other
Indication
Advanced PRAME Positive Cancers
Status
active
Trials
1